Emulsions, comprising dispersed oil or water droplets stabilized by surfactants, are widely employed across industries. However, conventional surfactants raise environmental concerns, and emulsions may encounter stability challenges during storage. A promising alternative lies in Pickering emulsions, where particles adhere irreversibly at the water-oil interface, providing enhanced stability. Recent research explores the use of natural bio-based particles as interfacial stabilizers for creating Pickering emulsions, offering improved stability and environmental friendliness. This significant change towards particle-stabilized emulsions addresses sustainability and efficacy concerns. This dissertation investigates the application of cellulose nanofibrils (CNFs) in stabilizing Pickering emulsions for the development of functional microcapsules with diverse applications. A novel CNF aerogel with a hierarchical pore structure was developed using n-hexane-CNF oil-in-water (O/W) Pickering emulsions as templates. These hollow microcapsule-based CNF (HM-CNF) aerogels demonstrated high oil absorption capacities of 354 grams per gram for chloroform and 166 grams per gram for n-hexadecane, without requiring hydrophobic modifications, highlighting their potential as environmentally sustainable and high-performance oil absorbents. Further, the research explored the microencapsulation of n-hexadecane, an organic phase change material (PCM), within a hybrid shell of CNFs and chitin nanofibers (ChNFs). This method significantly improved the thermal stability of the encapsulated n-hexadecane, with maximum weight loss temperatures increasing from 184 degrees Celsius to 201 degrees Celsius with ChNF loading. The char yield also increased with ChNF content, indicating enhanced thermal degradation resistance. These emulsions demonstrated stability in various ionic solutions and elevated temperatures, showcasing their potential for applications such as thermal energy storage, cosmetics, food, and pharmaceuticals. Additionally, the dissertation examined stable water-in-oil (W/O) inverse Pickering emulsions using TEMPO-treated cellulose nanofibrils (TCNF). These emulsions, stabilized by TCNF-oleylamine complexes, exhibited droplet sizes ranging from 27 micrometers to 8 micrometers depending on TCNF concentration. They maintained stability under varying pH, ionic strength, and temperature conditions and demonstrated the encapsulation of water-soluble components like phytic acid, highlighting their versatility for diverse encapsulation applications. Overall, the research presents significant advancements in the utilization of CNF-stabilized Pickering emulsions, employing them as templates for fabricating aerogels and microcapsules. This approach enhances oil absorption, thermal stability, and encapsulation capabilities, offering eco-friendly solutions for diverse applications.

L’immuno-isolation des îlots de Langerhans est proposée comme moyen d’effectuer des transplantations sans prise d’immunosuppresseurs par le patient. Cette immuno-isolation, par l’entremise d’une microcapsule composée d’alginate et de poly-L-lysine (microcapsule APA), protège le greffon d’une éventuelle attaque du système immunitaire du receveur grâce à sa membrane semi-perméable. Cette membrane empêche le système immunitaire du receveur de pénétrer la microcapsule tout en laissant diffuser librement les nutriments, le glucose et l’insuline. Avant l’application de cette technique chez l’humain, quelques défis doivent encore être relevés, dont la biocompatibilité de ce système. La biocompatibilité fait ici référence à la biocompatibilité du biomatériau utilisé pour la fabrication des microcapsules, l’alginate, mais aussi la biocompatibilité des microcapsules reliée à leur stabilité. En effet, il a été remarqué que, lors d’implantation in vivo de microcapsules fabriquées avec de l’alginate non purifiée, ceci induisait un phénomène nommé Réaction de l’Hôte contre la Microcapsule (RHM). De plus, il est connu que la stabilité des microcapsules APA peut influencer leur biocompatibilité puisqu’une microcapsule endommagée ou brisée pourrait laisser s’échapper les cellules du greffon chez le receveur. Nous croyons qu’une compréhension des processus d’initiation de la RHM en fonction de l’efficacité des procédés de purification d’alginate (et donc des quantités de contaminants présents dans l’alginate) ainsi que l’augmentation de la stabilité des microcapsules APA pourront améliorer la biocompatibilité de ce dispositif, ce que tente de démontrer les résultats présentés dans cette thèse. En effet, les résultats obtenus suggèrent que les protéines qui contaminent l’alginate jouent un rôle clé dans l’initiation de la RHM et qu’en diminuant ces quantités de protéines par l’amélioration des procédés de purification d’alginate, on améliore la biocompatibilité de l’alginate. Afin d’augmenter la stabilité des microcapsules APA, nous décrivons une nouvelle technique de fabrication des microcapsules qui implique la présence de liaisons covalentes. Ces nouvelles microcapsules APA réticulées sont très résistantes, n’affectent pas de façon négative la survie des cellules encapsulées et confinent les cellules du greffon à l’intérieur des microcapsules. Cette dernière caractéristique nous permet donc d’augmenter la biocompatibilité des microcapsules APA en protégeant le receveur contre les cellules du greffon. / Islet of Langerhans inmmunoisolation is proposed as a way to avoid the use of immunosuppressive drugs after transplantation. Microcapsules, the immuno-isolating device, are composed of alginate and poly-L-lysine and the protection of the graft is granted by a semi-permeable membrane. This membrane allows small molecules to freely diffuse within the microcapsule, such as nutrients, glucose and insulin while protecting the graft against the host immune system. Biocompatibility is one of the challenges that must be addressed before the successful clinical application of this device. Microcapsules biocompatibility is related, first, to the biocompatibility of alginate, the polymer used to made microcapsules and second, to the in vivo stability of these microcapsules. In facts, it is well know that the use of an unpurified alginate containing many foreign contaminants to make microcapsules induce the host reaction against microcapsule (HRM). Moreover, damaged or broken microcapsules can allow the dissemination of cells from the encapsulated graft, activating the host immune system. We believe that a better understanding of the initiation processes of the HRM in terms of alginate purification efficacy to remove contamination as well as an improve microcapsule stability will increase microcapsules biocompatibility. Results reported in this thesis suggest that foreign proteins found in alginate are playing a key role in the initiation of HRM and that the reduction of these foreign proteins, by the improvement of alginate purification processes, improves microcapsules biocompatibility. In order to increase microcapsules stability, we also described and characterized an innovative type of microcapsules which involve covalent bonds. These covalently cross-linked microcapsules were found to by highly resistant and stable. The novel fabrication process of these microcapsules was not harmful for the encapsulated cell survival and was also found to confine the graft inside the microcapsules. This characteristic enables us to increase microcapsules biocompatibility by the protection of the host from the encapsulated cells.

Un papier bioactif est obtenu par la modification d’un papier en y immobilisant une ou plusieurs biomolécules. La recherche et le développement de papiers bioactifs est en plein essor car le papier est un substrat peu dispendieux qui est déjà d’usage très répandu à travers le monde. Bien que les papiers bioactifs n’aient pas connus de succès commercial depuis la mise en marche de bandelettes mesurant le taux de glucose dans les années cinquante, de nombreux groupes de recherche travaillent à immobiliser des biomolécules sur le papier pour obtenir un papier bioactif qui est abordable et possède une bonne durée de vie. Contrairement à la glucose oxidase, l’enzyme utilisée sur ces bandelettes, la majorité des biomolécules sont très fragiles et perdent leur activité très rapidement lorsqu’immobilisées sur des papiers. Le développement de nouveaux papiers bioactifs pouvant détecter des substances d’intérêt ou même désactiver des pathogènes dépend donc de découverte de nouvelles techniques d’immobilisation des biomolécules permettant de maintenir leur activité tout en étant applicable dans la chaîne de production actuelle des papiers fins. Le but de cette thèse est de développer une technique d’immobilisation efficace et versatile, permettant de protéger l’activité de biomolécules incorporées sur des papiers. La microencapsulation a été choisie comme technique d’immobilisation car elle permet d’enfermer de grandes quantités de biomolécules à l’intérieur d’une sphère poreuse permettant leur protection. Pour cette étude, le polymère poly(éthylènediimine) a été choisi afin de générer la paroi des microcapsules. Les enzymes laccase et glucose oxidase, dont les propriétés sont bien établies, seront utilisées comme biomolécules test. Dans un premier temps, deux procédures d’encapsulation ont été développées puis étudiées. La méthode par émulsion produit des microcapsules de plus petits diamètres que la méthode par encapsulation utilisant un encapsulateur, bien que cette dernière offre une meilleure efficacité d’encapsulation. Par la suite, l’effet de la procédure d’encapsulation sur l’activité enzymatique et la stabilité thermique des enzymes a été étudié à cause de l’importance du maintien de l’activité sur le développement d’une plateforme d’immobilisation. L’effet de la nature du polymère utilisé pour la fabrication des capsules sur la conformation de l’enzyme a été étudié pour la première fois. Finalement, l’applicabilité des microcapsules de poly(éthylèneimine) dans la confection de papiers bioactifs a été démontré par le biais de trois prototypes. Un papier réagissant au glucose a été obtenu en immobilisant des microcapsules contenant l’enzyme glucose oxidase. Un papier sensible à l’enzyme neuraminidase pour la détection de la vaginose bactérienne avec une plus grande stabilité durant l’entreposage a été fait en encapsulant les réactifs colorimétriques dans des capsules de poly(éthylèneimine). L’utilisation de microcapsules pour l’immobilisation d’anticorps a également été étudiée. Les avancées au niveau de la plateforme d’immobilisation de biomolécules par microencapsulation qui ont été réalisées lors de cette thèse permettront de mieux comprendre l’effet des réactifs impliqués dans la procédure de microencapsulation sur la stabilité, l’activité et la conformation des biomolécules. Les résultats obtenus démontrent que la plateforme d’immobilisation développée peut être appliquée pour la confection de nouveaux papiers bioactifs. / Biosensing paper attracts increasing attention due to its benefits of being simple, visible, portable and useful for detecting various contaminants, pathogens and toxins. While there has been no bioactive paper commercialized since glucose paper strips developed in the fifties, many research groups are working to immobilize biomolecules on paper to achieve a bioactive paper that is affordable and has good shelf life. The goal of this research is to develop some highly useful bioactive paper that could, for example, measure blood glucose, or immediately detect and simultaneously deactivate pathogens such as neuraminidase and E.coli. Previously, bioactive paper was produced either through physically absorbing biorecognition elements or printing bio-ink onto paper substrate. Our methodology for fabrication of bioactive paper strips is compatible with existing paper making process and includes three procedures: the fabrication of microcapsules, enzyme or antibody microencapsulation, immobilization of enzymes or antibody-entrapped microcapsules into paper pulp. The first step, in fabricating of bioactive paper strips is to produce biocompatible and inexpensive microcapsules with suitable parameters. To do so, two types of microencapsulation methods were compared; the emulsion method and the vibration nozzle method accomplished with an encapsulator. The parameters for producing optimal microcapsules with both methods were studied. Factors that affect their diameter, wall thickness, shell pore size, encapsulation efficiency and membrane compositions were also discussed. By comparison, microcapsules prepared with poly(ethyleneimine) (PEI) by the emulsion method exhibit properties that were more suitable for enzyme encapsulation and paper making process, whereas the microcapsules prepared by the vibration nozzle method were too big to be immobilized within paper pulp, and had lower encapsulation efficiency, enzymatic activity and productivity. Thus the emulsion method was chosen for subsequent experiments such as enzyme and antibody microencapsulation and bacterial vaginosis (BV) paper preparation. Microcapsules made by the emulsion method were semi-permeable in that the diffusion of substrate and product molecules were allowed freely across the membranes but the encapsulated enzymes would be retained inside. Glucose oxidase from Aspergillus niger (GOx) and laccase from Trametes versicolor (TvL) microcapsules showed high encapsulation efficiency, but the encapsulation process caused a severe decrease in the specific activities of both enzymes. Results from circular dichroism (CD) studies, fluorescence properties, enzymatic activities of free enzymes and Michaelis-Menten behavior demonstrated that the Vmax decrease for GOx was due to the restriction of diffusion across microcapsule membranes with pore size less than 5 nm. The microencapsulation process improved the thermal stability of GOx but decreased that of laccase. Bioactive papers were fabricated either by incorporating microcapsules containing different enzymes or empty microcapsules soaked in substrate and enhancer solution into the paper pulp during the sheet making process. Both the GOx and the BV paper strips underwent a color change in the presence of glucose and potassium iodide, and sialidase from Clostridium perfringens respectively. Some preliminary studies on antibody sensitized microcapsules, in which antibody was either encapsulated within the PEI microcapsules or conjugated to its membranes, were also performed. Our objective was to establish an enzyme immobilization platform based on microencapsulation techniques for paper based biosensors. Even though our current studies only focused on the microencapsulation of two enzymes, TvL and GOx, as well as the bioactive paper preparation, a similar approach can be applied to other enzymes. We believe that this immobilization method can potentially be employed for bioactive paper preparation on an industrial scale.

L’immuno-isolation des îlots de Langerhans est proposée comme moyen d’effectuer des transplantations sans prise d’immunosuppresseurs par le patient. Cette immuno-isolation, par l’entremise d’une microcapsule composée d’alginate et de poly-L-lysine (microcapsule APA), protège le greffon d’une éventuelle attaque du système immunitaire du receveur grâce à sa membrane semi-perméable. Cette membrane empêche le système immunitaire du receveur de pénétrer la microcapsule tout en laissant diffuser librement les nutriments, le glucose et l’insuline. Avant l’application de cette technique chez l’humain, quelques défis doivent encore être relevés, dont la biocompatibilité de ce système. La biocompatibilité fait ici référence à la biocompatibilité du biomatériau utilisé pour la fabrication des microcapsules, l’alginate, mais aussi la biocompatibilité des microcapsules reliée à leur stabilité. En effet, il a été remarqué que, lors d’implantation in vivo de microcapsules fabriquées avec de l’alginate non purifiée, ceci induisait un phénomène nommé Réaction de l’Hôte contre la Microcapsule (RHM). De plus, il est connu que la stabilité des microcapsules APA peut influencer leur biocompatibilité puisqu’une microcapsule endommagée ou brisée pourrait laisser s’échapper les cellules du greffon chez le receveur. Nous croyons qu’une compréhension des processus d’initiation de la RHM en fonction de l’efficacité des procédés de purification d’alginate (et donc des quantités de contaminants présents dans l’alginate) ainsi que l’augmentation de la stabilité des microcapsules APA pourront améliorer la biocompatibilité de ce dispositif, ce que tente de démontrer les résultats présentés dans cette thèse. En effet, les résultats obtenus suggèrent que les protéines qui contaminent l’alginate jouent un rôle clé dans l’initiation de la RHM et qu’en diminuant ces quantités de protéines par l’amélioration des procédés de purification d’alginate, on améliore la biocompatibilité de l’alginate. Afin d’augmenter la stabilité des microcapsules APA, nous décrivons une nouvelle technique de fabrication des microcapsules qui implique la présence de liaisons covalentes. Ces nouvelles microcapsules APA réticulées sont très résistantes, n’affectent pas de façon négative la survie des cellules encapsulées et confinent les cellules du greffon à l’intérieur des microcapsules. Cette dernière caractéristique nous permet donc d’augmenter la biocompatibilité des microcapsules APA en protégeant le receveur contre les cellules du greffon. / Islet of Langerhans inmmunoisolation is proposed as a way to avoid the use of immunosuppressive drugs after transplantation. Microcapsules, the immuno-isolating device, are composed of alginate and poly-L-lysine and the protection of the graft is granted by a semi-permeable membrane. This membrane allows small molecules to freely diffuse within the microcapsule, such as nutrients, glucose and insulin while protecting the graft against the host immune system. Biocompatibility is one of the challenges that must be addressed before the successful clinical application of this device. Microcapsules biocompatibility is related, first, to the biocompatibility of alginate, the polymer used to made microcapsules and second, to the in vivo stability of these microcapsules. In facts, it is well know that the use of an unpurified alginate containing many foreign contaminants to make microcapsules induce the host reaction against microcapsule (HRM). Moreover, damaged or broken microcapsules can allow the dissemination of cells from the encapsulated graft, activating the host immune system. We believe that a better understanding of the initiation processes of the HRM in terms of alginate purification efficacy to remove contamination as well as an improve microcapsule stability will increase microcapsules biocompatibility. Results reported in this thesis suggest that foreign proteins found in alginate are playing a key role in the initiation of HRM and that the reduction of these foreign proteins, by the improvement of alginate purification processes, improves microcapsules biocompatibility. In order to increase microcapsules stability, we also described and characterized an innovative type of microcapsules which involve covalent bonds. These covalently cross-linked microcapsules were found to by highly resistant and stable. The novel fabrication process of these microcapsules was not harmful for the encapsulated cell survival and was also found to confine the graft inside the microcapsules. This characteristic enables us to increase microcapsules biocompatibility by the protection of the host from the encapsulated cells.

Un papier bioactif est obtenu par la modification d’un papier en y immobilisant une ou plusieurs biomolécules. La recherche et le développement de papiers bioactifs est en plein essor car le papier est un substrat peu dispendieux qui est déjà d’usage très répandu à travers le monde. Bien que les papiers bioactifs n’aient pas connus de succès commercial depuis la mise en marche de bandelettes mesurant le taux de glucose dans les années cinquante, de nombreux groupes de recherche travaillent à immobiliser des biomolécules sur le papier pour obtenir un papier bioactif qui est abordable et possède une bonne durée de vie. Contrairement à la glucose oxidase, l’enzyme utilisée sur ces bandelettes, la majorité des biomolécules sont très fragiles et perdent leur activité très rapidement lorsqu’immobilisées sur des papiers. Le développement de nouveaux papiers bioactifs pouvant détecter des substances d’intérêt ou même désactiver des pathogènes dépend donc de découverte de nouvelles techniques d’immobilisation des biomolécules permettant de maintenir leur activité tout en étant applicable dans la chaîne de production actuelle des papiers fins. Le but de cette thèse est de développer une technique d’immobilisation efficace et versatile, permettant de protéger l’activité de biomolécules incorporées sur des papiers. La microencapsulation a été choisie comme technique d’immobilisation car elle permet d’enfermer de grandes quantités de biomolécules à l’intérieur d’une sphère poreuse permettant leur protection. Pour cette étude, le polymère poly(éthylènediimine) a été choisi afin de générer la paroi des microcapsules. Les enzymes laccase et glucose oxidase, dont les propriétés sont bien établies, seront utilisées comme biomolécules test. Dans un premier temps, deux procédures d’encapsulation ont été développées puis étudiées. La méthode par émulsion produit des microcapsules de plus petits diamètres que la méthode par encapsulation utilisant un encapsulateur, bien que cette dernière offre une meilleure efficacité d’encapsulation. Par la suite, l’effet de la procédure d’encapsulation sur l’activité enzymatique et la stabilité thermique des enzymes a été étudié à cause de l’importance du maintien de l’activité sur le développement d’une plateforme d’immobilisation. L’effet de la nature du polymère utilisé pour la fabrication des capsules sur la conformation de l’enzyme a été étudié pour la première fois. Finalement, l’applicabilité des microcapsules de poly(éthylèneimine) dans la confection de papiers bioactifs a été démontré par le biais de trois prototypes. Un papier réagissant au glucose a été obtenu en immobilisant des microcapsules contenant l’enzyme glucose oxidase. Un papier sensible à l’enzyme neuraminidase pour la détection de la vaginose bactérienne avec une plus grande stabilité durant l’entreposage a été fait en encapsulant les réactifs colorimétriques dans des capsules de poly(éthylèneimine). L’utilisation de microcapsules pour l’immobilisation d’anticorps a également été étudiée. Les avancées au niveau de la plateforme d’immobilisation de biomolécules par microencapsulation qui ont été réalisées lors de cette thèse permettront de mieux comprendre l’effet des réactifs impliqués dans la procédure de microencapsulation sur la stabilité, l’activité et la conformation des biomolécules. Les résultats obtenus démontrent que la plateforme d’immobilisation développée peut être appliquée pour la confection de nouveaux papiers bioactifs. / Biosensing paper attracts increasing attention due to its benefits of being simple, visible, portable and useful for detecting various contaminants, pathogens and toxins. While there has been no bioactive paper commercialized since glucose paper strips developed in the fifties, many research groups are working to immobilize biomolecules on paper to achieve a bioactive paper that is affordable and has good shelf life. The goal of this research is to develop some highly useful bioactive paper that could, for example, measure blood glucose, or immediately detect and simultaneously deactivate pathogens such as neuraminidase and E.coli. Previously, bioactive paper was produced either through physically absorbing biorecognition elements or printing bio-ink onto paper substrate. Our methodology for fabrication of bioactive paper strips is compatible with existing paper making process and includes three procedures: the fabrication of microcapsules, enzyme or antibody microencapsulation, immobilization of enzymes or antibody-entrapped microcapsules into paper pulp. The first step, in fabricating of bioactive paper strips is to produce biocompatible and inexpensive microcapsules with suitable parameters. To do so, two types of microencapsulation methods were compared; the emulsion method and the vibration nozzle method accomplished with an encapsulator. The parameters for producing optimal microcapsules with both methods were studied. Factors that affect their diameter, wall thickness, shell pore size, encapsulation efficiency and membrane compositions were also discussed. By comparison, microcapsules prepared with poly(ethyleneimine) (PEI) by the emulsion method exhibit properties that were more suitable for enzyme encapsulation and paper making process, whereas the microcapsules prepared by the vibration nozzle method were too big to be immobilized within paper pulp, and had lower encapsulation efficiency, enzymatic activity and productivity. Thus the emulsion method was chosen for subsequent experiments such as enzyme and antibody microencapsulation and bacterial vaginosis (BV) paper preparation. Microcapsules made by the emulsion method were semi-permeable in that the diffusion of substrate and product molecules were allowed freely across the membranes but the encapsulated enzymes would be retained inside. Glucose oxidase from Aspergillus niger (GOx) and laccase from Trametes versicolor (TvL) microcapsules showed high encapsulation efficiency, but the encapsulation process caused a severe decrease in the specific activities of both enzymes. Results from circular dichroism (CD) studies, fluorescence properties, enzymatic activities of free enzymes and Michaelis-Menten behavior demonstrated that the Vmax decrease for GOx was due to the restriction of diffusion across microcapsule membranes with pore size less than 5 nm. The microencapsulation process improved the thermal stability of GOx but decreased that of laccase. Bioactive papers were fabricated either by incorporating microcapsules containing different enzymes or empty microcapsules soaked in substrate and enhancer solution into the paper pulp during the sheet making process. Both the GOx and the BV paper strips underwent a color change in the presence of glucose and potassium iodide, and sialidase from Clostridium perfringens respectively. Some preliminary studies on antibody sensitized microcapsules, in which antibody was either encapsulated within the PEI microcapsules or conjugated to its membranes, were also performed. Our objective was to establish an enzyme immobilization platform based on microencapsulation techniques for paper based biosensors. Even though our current studies only focused on the microencapsulation of two enzymes, TvL and GOx, as well as the bioactive paper preparation, a similar approach can be applied to other enzymes. We believe that this immobilization method can potentially be employed for bioactive paper preparation on an industrial scale.

Diabetes mellitus tipo 1 resulta da produção insuficiente ou da ausência de insulina, decorrente da destruição de células β, por mecanismo auto-imune. O tratamento deste tipo de diabetes consiste na administração subcutânea de insulina exógena. Recentemente, foi demonstrado que o transplante de ilhotas pancreáticas é capaz de tornar o portador de diabetes tipo 1 independente de insulina exógena. Apesar do sucesso alcançado, a necessidade permanente de imunossupressão é uma das principais barreiras para que o transplante de ilhotas possa ser realizado em número maior de pacientes. Assim, o desenvolvimento de novas metodologias que evitem a rejeição do enxerto, como o macro e o microencapsulamento de ilhotas, continua sendo crucial para o estabelecimento definitivo do transplante de ilhotas como opção terapêutica no tratamento de diabetes tipo 1. Neste trabalho, foi padronizado um modelo animal para avaliar, in vivo, a funcionalidade das ilhotas pancreáticas humanas isoladas e purificadas na Unidade de Ilhotas Pancreáticas Humanas do IQUSP. Ratos NIH nude foram tornados diabéticos através de injeção de estreptozotocina para o implante de ilhotas pancreáticas humanas nuas e microencapsuladas. As ilhotas foram microencapsuladas em Biodritina, um novo heteropolissacarídeo patenteado e cedido ao nosso laboratório, tendo sido possível padronizar a produção de microcápsulas uniformes e homogêneas, com tamanho médio entre 400µm e 600 µm. A reversão do diabetes ocorreu em 24% dos ratos nude transplantados com ilhotas pancreáticas humanas nuas. Por outro lado, não observamos reversão do diabetes quando ilhotas encapsuladas foram implantadas, apesar do teste de atividade funcional realizado in vitro ter demonstrado que elas continuam a secretar insulina e a responder ao estímulo com glicose após o encapsulamento. Para elucidar este efeito, cápsulas vazias foram implantadas em ratos nude e em ratos imunocompetentes, os quais desenvolveram processo inflamatório acompanhado de processo fibrótico no local do implante. Estudo imuno-histoquímico está sendo realizado para esclarecer a natureza e a intensidade destes processos. / Type 1 diabetes mellitus results from insufficient or absence of insulin production, as a consequence of destruction of pancreatic β cells, by an auto-imune mechanism. Treatment for this type of diabetes consists of subcutaneous administration of exogenous insulin. Recently, it has been demonstrated that pancreatic islet cell transplantation is capable of rendering type I diabetic patients independent of exogenous insulin. However, in spite of the success achieved, permanent immunosuppression is still required, being the main barrier to expand this treatment to a large number of patients. Therefore, development of new technologies, such as islet macro and microencapsulation to avoid rejection of the tissue implanted, is still crucial for definitive establishment of islet transplantation as a therapeutic alternative for type I diabetes. In the present work, an animal model was established for in vivo evaluation of the functional ability of human pancreatic islets, which were isolated and purified at the Human Pancreatic Islet Unit of the University of São Paulo Chemistry Institute. Diabetes was induced in NIH nude rats through streptozotocin injection followed by implantation of naked or microencapsulated human pancreatic islets. Biodritin, a new and patented heteropolyssaccaride was used to microencapsulate the islets. The production of uniform and homogeneous microcapsules with diameters in the range of 400µm e 600 µm was successfully established. Reversion of diabetes occurred in 24% of the nude rats transplanted with human pancreatic islets. On the other hand, no reversion of diabetes was observed when encapsulated islets were implanted, although their functional activity in vitro indicated that they secreted insulin and responded to glucose stimulation upon encapsulation. In order to elucidate this effect, empty capsules were implanted in nude rat and in immunocompetent rats, both of which developed an inflammatory process accompanied by a fibrotic process in the site of the implant. Immunohistochemical studies are underway to address the nature and the intensity of these inflammatory processes.

A Doença de Chagas atualmente atinge a vida de aproximadamente 18 milhões de portadores do parasita. Assim, este trabalho, parte de um estudo mais amplo, teve como objetivo avaliar a atividade biológica de compostos nitro-heterocíclicos com estrutura análoga à nifuroxazida, 5-nitro-2-furfurilideno 4-hidroxibenzidrazida, frente à cepa Y de Trypanosoma cruzi antes e após a sua microencapsulação por coacervação complexa de gelatina e goma-arábica, que, em geral, se mostram pouco solúveis nos meios e concentração empregados em testes farmacológicos, indicando a necessidade do desenvolvimento de um sistema vetorial que poderá melhorar o perfil farmacológico destes compostos. Assim, padronizou-se técnica de microencapsulação, a partir de resultados de ensaios preliminares e dados da literatura, e empregou-se dois métodos de secagem das microcápsulas, a saber: álcoois e atomização. Exame microscópico dos produtos secos confirmou a formação das microcápsulas possibilitando visualizar a diferença entre os produtos obtidos pelos dois métodos de secagem, para os quais, obteve-se rendimento de microcápsulas de 76±3,6 % e 61±5, 1 % e porcentagem de microencapsulação de 66±12,0 e 24,5±5,3 respectivamente. Obteve-se curva de absorção e de calibração dos compostos analisados, em DMSO, observando-se que não há interferência do complexo gelatina-goma arábica sobre a absorção UV dos compostos possibilitando determinação confiável da concentração destes nas microcápsulas. Ensaios in vitro demonstraram a não interferência do material de encapsulação e do solvente utilizado (DMSO 5%) sobre o desenvolvimento parasitário. Os compostos puros (50 µg/mL) se mostraram bastante ativos eliminando 100% das formas parasitárias em 48 horas, enquanto que, com benznidazol (100 µg/ml) no 12º dia de experimento ainda haviam formas evolutivas viáveis. Os produtos secos por atomização tiveram um comportamento antichagásico semelhante aos compostos puros reduzindo a população parasitária em 63±10% em 24 horas (64±13% compostos puros) não sendo um método adequado para liberação prolongada. Os produtos secos por álcoois permitiram este tipo de liberação devido à integridade das microcápsulas, observada ao microscópio, e em 24 horas houve redução de apenas 20±9% da população, necessitando de 96 horas para eliminação total dos parasitas. Assim, a microencapsulação e a secagem por álcoois utilizados resultaram em liberação lenta dos nitro compostos indicando a possibilidade de utilização deste sistema vetor em estudos mais aprofundados com vistas a melhorar a eficácia antichagásica desses compostos. / Chagas\' Disease reaches whole Latin America exposing 100 million people to infection risk, harming seriously 18 million patients\' life. Thus, the aim of this work was evaluate biological activity of nitro-heterocyclics compounds with similar structure of nifuroxazide, 5-nitro-2-furaldehyde p-hydroxy-benzoylhydrazone, against Trypanosoma cruzi, strain Y, before and after microencapsulation by complex coacervation of gelatin and gum arabic. These compounds, in general, are poorly soluble in concentration used in pharmacological tests, thus the development of a vectorial system will improve pharmacological profile of them. Microencapsulation method was defined based on literature data and preliminary assays and it was used two drying methods: isopropanol-ethanol addition, or spray-drying. Microscopic examination of dried products shown morphological difference between alcohols and spray-dried microcapsules. Microencapsulation percentage average yields were 66.0±12.0% and 24.5±5.3% and coacervate yields were 76.0±3.6% and 61.0±5.1% respectively. After determination of λMAX and standard curves, with DMSO, it was observed no interference of gelatin-acacia complex in UV absorption, making possible reliable dosage of nitro-compounds in microcapsules. ln vitro studies have not shown interference of unloaded microcapsules or DMSO 5% on parasites growth. Solutions used of free nitro-heterocyclics (50 µg/mL) were plenty active against T. cruzi, have shown population reduction of 100% in 48 hours, however, benznidazol (100 &#181g/mL) in 12th day experiment there were still viable parasitic forms. Dried products by spray-drying had antichagasic behavior similar to pure compounds, with parasitic population reduction of 63±10% in 24 hours (64±13% pure compounds) not being appropriate method for extended release. Dried products by alcohols allowed this liberation type due to integrity of microcapsules, observed by microscope, and in 24 hours there was reduction of only 20±9% of the population, needing 96 hours for total parasites\' elimination. Thus, microencapsulation and drying method useing alcohols resulted in slow liberation rates of nitro compounds indicating the possibility of use this vectorial system in studies with views to improve the antichagasic effect of those compounds.

A Doença de Chagas atualmente atinge a vida de aproximadamente 18 milhões de portadores do parasita. Assim, este trabalho, parte de um estudo mais amplo, teve como objetivo avaliar a atividade biológica de compostos nitro-heterocíclicos com estrutura análoga à nifuroxazida, 5-nitro-2-furfurilideno 4-hidroxibenzidrazida, frente à cepa Y de Trypanosoma cruzi antes e após a sua microencapsulação por coacervação complexa de gelatina e goma-arábica, que, em geral, se mostram pouco solúveis nos meios e concentração empregados em testes farmacológicos, indicando a necessidade do desenvolvimento de um sistema vetorial que poderá melhorar o perfil farmacológico destes compostos. Assim, padronizou-se técnica de microencapsulação, a partir de resultados de ensaios preliminares e dados da literatura, e empregou-se dois métodos de secagem das microcápsulas, a saber: álcoois e atomização. Exame microscópico dos produtos secos confirmou a formação das microcápsulas possibilitando visualizar a diferença entre os produtos obtidos pelos dois métodos de secagem, para os quais, obteve-se rendimento de microcápsulas de 76±3,6 % e 61±5, 1 % e porcentagem de microencapsulação de 66±12,0 e 24,5±5,3 respectivamente. Obteve-se curva de absorção e de calibração dos compostos analisados, em DMSO, observando-se que não há interferência do complexo gelatina-goma arábica sobre a absorção UV dos compostos possibilitando determinação confiável da concentração destes nas microcápsulas. Ensaios in vitro demonstraram a não interferência do material de encapsulação e do solvente utilizado (DMSO 5%) sobre o desenvolvimento parasitário. Os compostos puros (50 µg/mL) se mostraram bastante ativos eliminando 100% das formas parasitárias em 48 horas, enquanto que, com benznidazol (100 µg/ml) no 12º dia de experimento ainda haviam formas evolutivas viáveis. Os produtos secos por atomização tiveram um comportamento antichagásico semelhante aos compostos puros reduzindo a população parasitária em 63±10% em 24 horas (64±13% compostos puros) não sendo um método adequado para liberação prolongada. Os produtos secos por álcoois permitiram este tipo de liberação devido à integridade das microcápsulas, observada ao microscópio, e em 24 horas houve redução de apenas 20±9% da população, necessitando de 96 horas para eliminação total dos parasitas. Assim, a microencapsulação e a secagem por álcoois utilizados resultaram em liberação lenta dos nitro compostos indicando a possibilidade de utilização deste sistema vetor em estudos mais aprofundados com vistas a melhorar a eficácia antichagásica desses compostos. / Chagas\' Disease reaches whole Latin America exposing 100 million people to infection risk, harming seriously 18 million patients\' life. Thus, the aim of this work was evaluate biological activity of nitro-heterocyclics compounds with similar structure of nifuroxazide, 5-nitro-2-furaldehyde p-hydroxy-benzoylhydrazone, against Trypanosoma cruzi, strain Y, before and after microencapsulation by complex coacervation of gelatin and gum arabic. These compounds, in general, are poorly soluble in concentration used in pharmacological tests, thus the development of a vectorial system will improve pharmacological profile of them. Microencapsulation method was defined based on literature data and preliminary assays and it was used two drying methods: isopropanol-ethanol addition, or spray-drying. Microscopic examination of dried products shown morphological difference between alcohols and spray-dried microcapsules. Microencapsulation percentage average yields were 66.0±12.0% and 24.5±5.3% and coacervate yields were 76.0±3.6% and 61.0±5.1% respectively. After determination of λMAX and standard curves, with DMSO, it was observed no interference of gelatin-acacia complex in UV absorption, making possible reliable dosage of nitro-compounds in microcapsules. ln vitro studies have not shown interference of unloaded microcapsules or DMSO 5% on parasites growth. Solutions used of free nitro-heterocyclics (50 µg/mL) were plenty active against T. cruzi, have shown population reduction of 100% in 48 hours, however, benznidazol (100 &#181g/mL) in 12th day experiment there were still viable parasitic forms. Dried products by spray-drying had antichagasic behavior similar to pure compounds, with parasitic population reduction of 63±10% in 24 hours (64±13% pure compounds) not being appropriate method for extended release. Dried products by alcohols allowed this liberation type due to integrity of microcapsules, observed by microscope, and in 24 hours there was reduction of only 20±9% of the population, needing 96 hours for total parasites\' elimination. Thus, microencapsulation and drying method useing alcohols resulted in slow liberation rates of nitro compounds indicating the possibility of use this vectorial system in studies with views to improve the antichagasic effect of those compounds.

Bifidobacterium spp. são microrganismos probióticos que podem ser incorporados em produtos alimentícios. Entretanto, para que seus efeitos benéficos à saúde humana ocorram, é necessário que o número de células viáveis na hora do consumo seja, no mínimo, 106UFC/g. As bifidobactérias são sensíveis à elevada acidez e, por isso, torna-se necessária a busca por métodos que possam proteger a integridade da célula, sendo um deles a microencapsulação. Em uma primeira etapa do trabalho, Bifidobacterium lactis foi encapsulado em micropartículas de alginato e alginato modificado (alginatoquitosana, alginato-quitosana-sureteric e alginato-quitosana-acryl-eze) e sua sobrevivência e liberação das micropartículas em fluidos simulados do trato gastrintestinal foram mensuradas utilizando-se soluções tampão com pH 1,5, 5,6 e 7,5, na presença e na ausência de pepsina (3g/L), pancreatina (1g/L) e bile (10g/L). A liberação de células das micropartículas teve uma relação direta com o pH do tampão. A microencapsulação aumentou a taxa de sobrevivência de B. lactis, em comparação com células não encapsuladas, em soluções tampão com pH 1,5 sem a presença de enzimas. Em suco gástrico simulado com enzimas digestivas, por outro lado, foi observado que a pepsina proporcionou um efeito protetor sobre as células de B. lactis, e nesse caso, as taxas de sobrevivência do microrganismo estavam diretamente relacionadas com o grau de injúria das células. Em uma segunda etapa do trabalho, leites fermentados com Streptococcus salivarius ssp. thermophilus e Lactobacillus delbrueckii ssp. bulgaricus foram enriquecidos com culturas de Bifidobacterium lactis submetidas a quatro tratamentos diferentes: desidratação em temperatura ambiente, liofilização/congelamento, encapsulação em alginatoquitosana e encapsulação em alginato-quitosana-acryl-eze. A população sobrevivente de B. lactis foi determinada semanalmente no leite fermentado e também após tratamento simulando condições do trato gastrintestinal. Os resultados indicaram que na ausência de pepsina, as populações de B. lactis foram reduzidas drasticamente após o contato com tampão pH 1,5, não sendo possível a detecção de células viáveis livres ou encapsuladas após 120 minutos de teste. A presença de pepsina influenciou positivamente a recuperação de células viáveis de B. lactis em todas as condições testadas, mas as culturas na forma desidratada apresentaram melhores resultados que as culturas microencapsuladas ou liofilizadas. No caso do leite fermentado contendo as células desidratadas, a população de B. lactis, após o tratamento em suco gástrico com enzimas, foi superior à detectada no produto antes desse tratamento. Conclui-se que a microencapsulação não foi eficiente para proteger B. lactis em leite fermentado contra injúrias causadas pelo trato gastrintestinal simulado. / Bifidobacterium spp. are microorganisms that can be added to foods. However, the benefits for the human health occur when the numbers of viable cells in the moment of the consumption is at least 106CFU/g. Bifidobacteria are acid sensitive, and methods to protect cell integrity, such as microencapsulation, are needed. In the first part of the present study, Bifidobacterium lactis was encapsulated in microparticles of alginate and modified alginate (alginate-chitosan, alginate-chitosan-sureteric and alginate-chitosan-acryl-eze) and the survival and release from microparticles in simulated gastrointestinal conditions were measured, using buffers (pH 1.5, 5.6 and 7.5), in the absence and presence of pepsin (3g/L), pancreatin (1g/L) and bile. The release from microparticles presented a direct relationship with pH. When the pH was 1.5 and no enzyme was present, encapsulation improved the survival of B. lactis, when compared to free cells. However, pepsin had a protective effect on B. lactis, and the survival rate was directly related to the cells injury degree. In the second part of the study, fermented milk samples containing Streptococcus salivarius ssp. thermophilus and Lactobacillus delbrueckii ssp. Bulgaricus were supplemented with B. lactis submitted to four different treatments: dehydration at room temperature, freeze drying, encapsulation in alginate-chitosan and encapsulation in alginate-chitosaacryl-eze. The number of viable B. lactis cells in the fermented milk was determined weekly and also after treatment with simulated gastrointestinal conditions. Results indicated that in the absence of pepsin, the number of viable cells decreased significantly after contact with buffers (pH 1.5), and no viable cell was detected after 120 minutes. Pepsin improved the recovery of viable cells in the assayed gastric conditions, being the dehydrated cultures more resistant than other cultures. In fermented milk containing the dehydrated cells, the number of viable cells increased after treatment with simulated gastrointestinal fluids. Microencapsulation was not an effective procedure to protect B. lactis in fermented milk against injury caused by the simulated gastrointestinal tract.

Diabetes mellitus tipo 1 resulta da produção insuficiente ou da ausência de insulina, decorrente da destruição de células β, por mecanismo auto-imune. O tratamento deste tipo de diabetes consiste na administração subcutânea de insulina exógena. Recentemente, foi demonstrado que o transplante de ilhotas pancreáticas é capaz de tornar o portador de diabetes tipo 1 independente de insulina exógena. Apesar do sucesso alcançado, a necessidade permanente de imunossupressão é uma das principais barreiras para que o transplante de ilhotas possa ser realizado em número maior de pacientes. Assim, o desenvolvimento de novas metodologias que evitem a rejeição do enxerto, como o macro e o microencapsulamento de ilhotas, continua sendo crucial para o estabelecimento definitivo do transplante de ilhotas como opção terapêutica no tratamento de diabetes tipo 1. Neste trabalho, foi padronizado um modelo animal para avaliar, in vivo, a funcionalidade das ilhotas pancreáticas humanas isoladas e purificadas na Unidade de Ilhotas Pancreáticas Humanas do IQUSP. Ratos NIH nude foram tornados diabéticos através de injeção de estreptozotocina para o implante de ilhotas pancreáticas humanas nuas e microencapsuladas. As ilhotas foram microencapsuladas em Biodritina, um novo heteropolissacarídeo patenteado e cedido ao nosso laboratório, tendo sido possível padronizar a produção de microcápsulas uniformes e homogêneas, com tamanho médio entre 400µm e 600 µm. A reversão do diabetes ocorreu em 24% dos ratos nude transplantados com ilhotas pancreáticas humanas nuas. Por outro lado, não observamos reversão do diabetes quando ilhotas encapsuladas foram implantadas, apesar do teste de atividade funcional realizado in vitro ter demonstrado que elas continuam a secretar insulina e a responder ao estímulo com glicose após o encapsulamento. Para elucidar este efeito, cápsulas vazias foram implantadas em ratos nude e em ratos imunocompetentes, os quais desenvolveram processo inflamatório acompanhado de processo fibrótico no local do implante. Estudo imuno-histoquímico está sendo realizado para esclarecer a natureza e a intensidade destes processos. / Type 1 diabetes mellitus results from insufficient or absence of insulin production, as a consequence of destruction of pancreatic β cells, by an auto-imune mechanism. Treatment for this type of diabetes consists of subcutaneous administration of exogenous insulin. Recently, it has been demonstrated that pancreatic islet cell transplantation is capable of rendering type I diabetic patients independent of exogenous insulin. However, in spite of the success achieved, permanent immunosuppression is still required, being the main barrier to expand this treatment to a large number of patients. Therefore, development of new technologies, such as islet macro and microencapsulation to avoid rejection of the tissue implanted, is still crucial for definitive establishment of islet transplantation as a therapeutic alternative for type I diabetes. In the present work, an animal model was established for in vivo evaluation of the functional ability of human pancreatic islets, which were isolated and purified at the Human Pancreatic Islet Unit of the University of São Paulo Chemistry Institute. Diabetes was induced in NIH nude rats through streptozotocin injection followed by implantation of naked or microencapsulated human pancreatic islets. Biodritin, a new and patented heteropolyssaccaride was used to microencapsulate the islets. The production of uniform and homogeneous microcapsules with diameters in the range of 400µm e 600 µm was successfully established. Reversion of diabetes occurred in 24% of the nude rats transplanted with human pancreatic islets. On the other hand, no reversion of diabetes was observed when encapsulated islets were implanted, although their functional activity in vitro indicated that they secreted insulin and responded to glucose stimulation upon encapsulation. In order to elucidate this effect, empty capsules were implanted in nude rat and in immunocompetent rats, both of which developed an inflammatory process accompanied by a fibrotic process in the site of the implant. Immunohistochemical studies are underway to address the nature and the intensity of these inflammatory processes.